Cognitive impairment with diabetes mellitus and metabolic disease: innovative insights with the mechanistic target of rapamycin and circadian clock gene pathways.

abstract：INTRODUCTION:More than half of the patients with inflammatory bowel disease (IBD) experience at least one extra-intestinal manifestation (EIM). The most common EIM in patients with IBD is spondyloarthritis (SpA). Microscopic intestinal inflammation is documented in almost 50% of the patients with SpA. Areas covered: We...

journal_title：Expert review of clinical pharmacology

authors： Pouillon L,Bossuyt P,Vanderstukken J,Moulin D,Netter P,Danese S,Jouzeau JY,Loeuille D,Peyrin-Biroulet L

更新日期：2017-12-01 00:00:00

abstract：INTRODUCTION:In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy and safety is not well characterized. Different efficacy and safety profiles in children of varying ages may be anticipated, due to developmental changes occurring across pediatric life. AREAS COVERED:Beside pharmacokine...

journal_title：Expert review of clinical pharmacology

authors： Brussee JM,Calvier EA,Krekels EH,Välitalo PA,Tibboel D,Allegaert K,Knibbe CA

更新日期：2016-09-01 00:00:00

abstract：INTRODUCTION:Anti-vascular endothelial growth factor (VEGF) therapy has become the most commonly used treatment for macular edema secondary to retinal vein occlusion (RVO). Although its superior efficacy as compared to other interventions has been proven, there is a lack of evidence for relative efficacy among anti-VEG...

journal_title：Expert review of clinical pharmacology

authors： Sangroongruangsri S,Ratanapakorn T,Wu O,Anothaisintawee T,Chaikledkaew U

更新日期：2018-09-01 00:00:00

abstract：:Migraine is a common neurological syndrome that affects approximately 10-20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the pathogenesis of migraine and thus 5-HT1-receptor agonists are the principal drugs for acute migraine therapy. There are three classes ...

journal_title：Expert review of clinical pharmacology

authors： Reddy DS

更新日期：2013-05-01 00:00:00

abstract：:Naltrexone-bupropion is a recently approved drug combination for chronic weight management. In this article, we discuss the rationale for its use as a combination followed by a comprehensive review of safety and efficacy data from major preclinical, phase II and III clinical trials. ...

journal_title：Expert review of clinical pharmacology

authors： Ali KF,Shukla AP,Aronne LJ

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVES:To estimate the prevalence of polypharmacy (≥5 drugs) among adults and to analyze related factors. METHODS:Cross-sectional study with 1,159 interviewees distributed across 104 cities and 253 primary healthcare services delivered through the Brazilian Unified Health System. Polypharmacy-related factors were ...

journal_title：Expert review of clinical pharmacology

authors： Moreira T,Alvares-Teodoro J,Barbosa MM,Do Nascimento RCRM,Guerra Júnior AA,Acurcio FA

更新日期：2020-12-01 00:00:00

abstract：:Background: The RESORT trial showed no longer relapse free survival (RFS) with sorafenib following radical metastasectomy in metastatic renal cell carcinoma. We present the updated 42-month follow-up data. Methods: The phase II RESORT trial randomized patients to sorafenib or observation within 12 weeks from surgery. ...

journal_title：Expert review of clinical pharmacology

authors： Mennitto A,Verzoni E,Cognetti F,Miceli R,Milella M,Mosca A,Chiuri VE,Bearz A,Morelli F,Ortega C,Atzori F,Donini M,Claps M,Guadalupi V,Sepe P,Cappelletti V,de Braud FG,Procopio G

更新日期：2021-01-31 00:00:00

abstract：:Oncology is one of the areas of medicine with the most active research being conducted on new drugs. New pharmacological entities frequently enter the clinical arena, and therefore, the safety profile of anticancer products deserves continuous monitoring. However, only very severe and (unusual) suspected adverse drug ...

journal_title：Expert review of clinical pharmacology

authors： Tuccori M,Montagnani S,Capogrosso-Sansone A,Mantarro S,Antonioli L,Fornai M,Blandizzi C

更新日期：2015-01-01 00:00:00

abstract：:Introduction: Primary endpoints and inclusion/exclusion criteria of biologics and small oral molecules for psoriasis treatment have been evolving due to a better understanding of the pathogenesis and potential risks.Areas covered: We analyzed the designs of key phase 3 pivotal trials of all biologics and small oral mo...

journal_title：Expert review of clinical pharmacology

authors： Hsu SH,Tsai TF

更新日期：2020-03-01 00:00:00

abstract：INTRODUCTION:Osteoarthritis is the most common cause of arthritis and one of the main causes of chronic pain. Although opioids are frequently employed for chronic pain treatment, their usage for osteoarthritis pain remains controversial due to the associated adverse effects. Most guidelines reserve their use for refrac...

journal_title：Expert review of clinical pharmacology

authors： Ruiz Iban MA,Benavides J,Forero JP,Bittelman S,Martinez R,Mite MA,Diaz Heredia J,Ulloa S,Lizárraga Ferrand MM

更新日期：2018-01-01 00:00:00

abstract：:C-X-C chemokine receptor (CXCR)3 and its interferon(IFN)γ-dependent chemokines (CXCL10, CXCL9, CXCL11) are implicated in the immune-pathogenesis of autoimmune thyroiditis (AT), Graves disease (GD) and Graves Ophthalmopathy (GO). In tissue, recruited Th1 lymphocytes produce IFNγ, enhancing the tissue secretion of IFNγ-...

journal_title：Expert review of clinical pharmacology

authors： Fallahi P,Ferrari SM,Elia G,Nasini F,Colaci M,Giuggioli D,Vita R,Benvenga S,Ferri C,Antonelli A

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high ne...

journal_title：Expert review of clinical pharmacology

authors： Santini FC,Rudin CM

更新日期：2017-09-01 00:00:00

abstract：INTRODUCTION:Dapsone is a sulfone drug used to treat infectious conditions and also numerous dermatologic diseases. Fixed drug eruption is a distinctive adverse cutaneous reaction associated with the initial administration and subsequent delivery of a specific agent. Areas covered: The authors preformed a literature se...

journal_title：Expert review of clinical pharmacology

authors： Garcia D,Cohen PR

更新日期：2017-07-01 00:00:00

abstract：:The aim of this article was to assess the efficacy and safety of apremilast in treatment of psoriatic arthritis (PsA) with meta-analysis method. We included four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast with place...

journal_title：Expert review of clinical pharmacology

authors： Qu X,Zhang S,Tao L,Song Y

更新日期：2016-06-01 00:00:00

abstract：:Pregnancy represents a major challenge in the management of patients with systemic lupus erythematosus, with substantial risks to both mother and baby. Over the past 40 years there have been major improvements in outcomes. This partly relates to the discovery of the antiphospholipid syndrome, which has transformed man...

journal_title：Expert review of clinical pharmacology

authors： Karim MY,D'Cruz DP

更新日期：2010-11-01 00:00:00

abstract：:Introduction: Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered: The present review assesses the principal pharmacological strategies that have b...

journal_title：Expert review of clinical pharmacology

authors： Giacomelli A,de Rose S,Rusconi S

更新日期：2019-01-01 00:00:00

abstract：:In the management of chronic obstructive pulmonary disease (COPD), there is an unmet medical need for effective bronchodilator treatments that not only have a fast onset of action, but also a long duration of action and are delivered using a simple, easy-to-use device. Long-acting muscarinic antagonists such as glycop...

journal_title：Expert review of clinical pharmacology

authors： Molimard M,D'Andrea P

更新日期：2013-09-01 00:00:00

abstract：:The dramatic effectiveness of statins in improving the course of atherosclerotic cardiovascular disease tends to overshadow questions of statin intolerance. Thus after more than 25 years of clinical statin use, intolerance remains a poorly understood, frustrating issue for patients and providers. It has been extraordi...

journal_title：Expert review of clinical pharmacology

authors： Guyton JR,Campbell KB,Lakey WC

更新日期：2014-01-01 00:00:00

abstract：:The use of pharmacokinetic (PK) and pharmacodynamic (PD) data to inform antimalarial treatment regimens has accelerated in the past few decades, due in no small part to the stimulus provided by progressive development of parasite resistance to most of the currently available drugs. An understanding of the disposition,...

journal_title：Expert review of clinical pharmacology

authors： Davis TM,Moore BR,Salman S,Page-Sharp M,Batty KT,Manning L

更新日期：2016-01-01 00:00:00

abstract：:Valproic acid is approved for treatment of seizures and manic episodes of bipolar disorder, and continues to be one of the most commonly prescribed antiepileptic drugs in the world. Hepatotoxicity is a rare but serious side effect resulting from its use, particularly in young patients. This adverse effect does not dis...

journal_title：Expert review of clinical pharmacology

authors： Felker D,Lynn A,Wang S,Johnson DE

更新日期：2014-03-01 00:00:00

abstract：:Secukinumab (also known as AIN-457) is a human monoclonal antibody targeting IL-17A, which has been recently FDA-approved for the treatment of moderate to severe psoriasis and psoriatic arthritis with coexistent moderate to severe plaque psoriasis based on clinical trials demonstrating excellent efficacy. This review ...

journal_title：Expert review of clinical pharmacology

authors： Jaleel T,Elmets C,Weinkle A,Kassira S,Elewski B

更新日期：2016-01-01 00:00:00

abstract：:Data from clinical trials, retrospective and cross-sectional studies have quantified the metabolic changes associated with long-term use of antiepileptic drugs (AEDs). AEDs can be associated with weight gain or weight loss, although most are weight neutral. Weight gain is not only a cosmetic problem but also a risk fo...

journal_title：Expert review of clinical pharmacology

authors： Hamed SA

更新日期：2015-01-01 00:00:00

abstract：:The oxazolidinones are a new class of antibiotics whose mechanism of action is the inhibition of bacterial protein synthesis by binding to the 50S ribosomal subunit. Linezolid is the first member of this class of antibiotics to be approved by the US FDA and other regulatory bodies for the treatment of infections cause...

journal_title：Expert review of clinical pharmacology

authors： Tan TQ,Yogev R

更新日期：2008-07-01 00:00:00

abstract：INTRODUCTION:Long-acting injectable antipsychotics (LAIAs) were introduced to improve treatment adherence and tolerability of oral formulations. After risperidone was introduced as the first long-acting injectable second-generation antipsychotic, during the last five years olanzapine pamoate, once-monthly paliperidone ...

journal_title：Expert review of clinical pharmacology

authors： Bernardo M,Bioque M

更新日期：2016-07-01 00:00:00

abstract：:Introduction: The placenta is a temporary and unique organ that allows for the physical connection between a mother and fetus; this organ regulates the transport of gases and nutrients mediating the elimination of waste products contained in the fetal circulation. The placenta performs metabolic and excretion function...

journal_title：Expert review of clinical pharmacology

authors： Blanco-Castañeda R,Galaviz-Hernández C,Souto PCS,Lima VV,Giachini FR,Escudero C,Damiano AE,Barragán-Zúñiga LJ,Martínez-Aguilar G,Sosa-Macías M

更新日期：2020-03-01 00:00:00

abstract：INTRODUCTION:Diabetes mellitus is associated with increased cardiovascular disease (CVD) risk. Areas covered: Main goal of hypolipidemic treatment in diabetic patients is low-density lipoprotein cholesterol (LDL-C) lowering with the use of statins. Addition of ezetimibe is useful in diabetic patients who cannot achieve...

journal_title：Expert review of clinical pharmacology

authors： Filippatos TD,Florentin M,Georgoula M,Elisaf MS

更新日期：2017-02-01 00:00:00

abstract：:The anti-tumor activity of CpG-containing oligodeoxynucleotides (ODNs) has been well established in numerous animal models and confirmed in a number of early clinical trials. While the use of chemical modifications has effectively reduced the sensitivity of ODNs to nuclease degradation and a number of human trials hav...

journal_title：Expert review of clinical pharmacology

authors： Wilson KD,Tam YK

更新日期：2009-03-01 00:00:00

abstract：:After the introduction of anti-tumor necrosis factor (anti-TNF) agents, the clinical outcome of patients with Inflammatory Bowel Disease (IBD) has improved significantly. However, use of anti-TNF therapy is complicated by loss of response. In order to maintain remission, adequate serum levels are required. Hence, ther...

journal_title：Expert review of clinical pharmacology

authors： Strik AS,Bots SJ,D'Haens G,Löwenberg M

更新日期：2016-01-01 00:00:00

abstract：:Introduction: With the majority of elderly persons consuming multiple drugs, inappropriate drug use is a major issue in geriatric medicine. Areas covered: We reviewed PubMed, Embase, and Cochrane from inception to 1 May 2019 for potentially inappropriate use of medications, polypharmacy, and age-dependent changes in p...

journal_title：Expert review of clinical pharmacology

authors： Koren G,Nordon G,Radinsky K,Shalev V

更新日期：2019-08-01 00:00:00

abstract：:Methotrexate is an antifolate agent used in the treatment of various cancers and some autoimmune diseases. In oncology, methotrexate is frequently administered at a high dose (>1 g/m(2)) and comes with various procedures to reduce the occurrence of toxicity and particularly to ensure optimal renal elimination. Drug-dr...

journal_title：Expert review of clinical pharmacology

authors： Levêque D,Santucci R,Gourieux B,Herbrecht R

更新日期：2011-11-01 00:00:00